Most studies of oxaliplatin in advanced ovarian cancer have been conducted after relapse, or in patients refractory to other platinum compounds. Oxaliplatin monotherapy in this patient population produced response rates ranging from 16 to 27%. Missetti et al showd in 2000 that response rates were similar to those obtained with paclitaxel monotherapy (16 vs 17%).
Guidelines from NCCN state that oxaliplatin is an acceptable alternative chemotherapeutic regimen for recurrent epithelial ovarian cancer for Stage II, III, and IV patients with partial responses to their primary paclitaxel and platinum-based chemotherapeutic regimens. The guidelines note that oxaliplatin has been demonstrated to be active in recurrent epithelial ovarian cancer.
There are severalphase II studies that combine oxaliplatin with otehr drugs, such as Doxil, Xeloda and Avastin or another taxane.
Misset J, Vennin P, Chollet P, et al. Multicenter phase II/III study of oxaliplatin plus cyclophoshamide (C) [OXC] versus cisplatin (P)plus cyclophoshamide [CPC] in advanced chemonaive ovarian cancer (AOC) patients: Final results [abstract no. 1502]. 36th ProcAm Soc Clin Oncol; 2000 May 20-23; Denver
Viens P, Petit T, Yovine A, et al. A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patients. Ann Oncol. 2006;17(3):429-436.
Nicoletto MO, Falci C, Pianalto D, et al. Phase II study of pegylated liposomal doxorubicin and oxaliplatin in relapsed advanced ovarian cancer. Gynecol Oncol. 2006;100(2):318-323.
Misset JL, Vennin P, Chollet PH, et al. Multicenter phase II-III study of oxaliplatin plus cyclophosphamide vs. cisplatin plus cyclophosphamide in chemonaive advanced ovarian cancer patients. Ann Oncol. 2001;12(10):1411-1415.
Piccart MJ, Green JA, Lacave AJ, et al. Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group. J Clin Oncol. 2000;18(6):1193-1202.
National Comprehensive Cancer Network (NCCN). Ovarian cancer. Clinical Practice Guidelines in Oncology OV-E, 2013
J. Alexandre et al,Mucinous advanced epithelial ovarian carcinoma: clinical presentation and sensitivity to platinum-paclitaxel-based chemotherapy, the GINECO experience Ann Oncol Dec 1, 2010:2377-2381